Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.
Less knowledge about OTC products with potentially serious interactions linked to increased use
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban vs placebo.
Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.
AHA 2017 Scientific Sessions
Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.
This is an investigational use for Eliquis.
Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online in JAMA Cardiology.
Older patients, females, and those with comorbidities were more likely to be on multiple medications.